Abeona Therapeutics Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual report; the filing does not provide a clear standalone fourth-quarter financial summary. Abeona is a clinical-stage biopharmaceutical company developing gene and cell therapies for rare genetic diseases. Its lead clinical programs are EB-101 for RDEB and ABO-102 and ABO-101 for MPS IIIA and MPS IIIB.
Financial performance and position
| Metric | FY2020 / Dec. 31, 2020 | FY2019 / Dec. 31, 2019 |
|---|---|---|
| Revenue | $10.0 million | $0 |
| Research and development expense | $30.1 million | $48.6 million |
| General and administrative expense | $23.8 million | $20.7 million |
| Operating loss | $81.4 million | $77.1 million |
| Net loss | $84.2 million | $76.3 million |
| Basic and diluted loss per share | $0.91 | $1.51 |
| Cash, cash equivalents and short-term investments | $95.0 million | $129.3 million |
| Cash used in operating activities | $35.0 million | $62.8 million |
| Working capital | $55.8 million | $93.7 million |
Revenue was entirely from Taysha Gene Therapies sublicense and related agreements: $7.0 million for CLN1 and $3.0 million for Rett syndrome. The company reported no significant product revenue. Gross margin is not meaningful for this development-stage business, and the filing does not present a useful product margin measure.
FY2020 net loss included a $32.9 million non-cash impairment charge for REGENXBIO-licensed technology. Total assets were $151.2 million and stockholders’ equity was $102.6 million at year-end. Total liabilities were $48.6 million, including $31.5 million payable to the licensor, $1.8 million in PPP loan obligations, and $7.0 million in lease liabilities. The licensor payable is disputed and subject to arbitration.
Changes versus FY2019
- Revenue increased from zero to $10.0 million due to Taysha licensing transactions.
- R&D expense declined $18.5 million, primarily reflecting reduced clinical, manufacturing and development activity during COVID-19 disruptions, as well as planned internal retrovirus manufacturing for EB-101.
- G&A expense increased $3.1 million, including higher compensation and professional fees; compensation included severance associated with management changes.
- Net loss increased $8.0 million, principally because of the $32.9 million impairment and higher interest expense, partly offset by licensing revenue and lower R&D costs. Loss per share improved as the weighted-average share count rose materially following prior-period equity financing.
- Cash and investments fell $34.3 million; operating cash use was lower than in 2019. The 2020 investing outflow largely reflects purchases of short-term investments, not solely operating consumption.
Outlook, developments and risks
- Liquidity: Management said existing cash, cash equivalents and short-term investments were expected to fund operations for at least 12 months from the report date, but additional funding will be needed for planned development. Financing may dilute shareholders or require concessions on assets or programs.
- Clinical programs: The VIITAL Phase 3 EB-101 study began in 2020, was paused in March due to COVID-19 and resumed enrollment in June. The filing reports ongoing Phase 1/2 trials for ABO-102 and ABO-101. Updated data reported in February 2021 described biomarker and other clinical signals; these are not approval outcomes, and longer follow-up is needed, particularly for ABO-101 cognitive outcomes.
- Arbitration: REGENXBIO terminated its AAV9 license in May 2020. Abeona disputes $28 million of payments plus $3.5 million accrued interest at year-end; REGENXBIO seeks payment. The arbitration hearing took place in March 2021, with a decision expected in late Q2 or early Q3 2021. The outcome could affect cash obligations and rights to use AAV9 in certain programs.
- COVID-19 and execution: The pandemic disrupted trial enrollment, manufacturing and regulatory activity. Further disruption, patient recruitment challenges, manufacturing or supply problems, and regulatory delays could defer development.
- PPP loan: Abeona received approximately $1.8 million. Forgiveness was uncertain at filing; if not forgiven, the loan carries 1% interest and a two-year repayment term.
- Other risks: Abeona has a history of losses, no significant operating revenue, and no assurance of profitability. Key risks include clinical safety or efficacy failure, regulatory approval, manufacturing scale-up, third-party reliance, intellectual-property disputes, competition and future capital needs. The filing provides no specific financial guidance.
- Governance/listing: Following director resignations, the company disclosed that it did not then meet Nasdaq requirements for a majority-independent board and a fully independent three-member audit committee; it had until the earlier of its next annual meeting or September 27, 2021 to regain compliance.
Important facts for investors to verify
- Latest cash and investment balance, actual cash burn, and whether management’s stated 12-month funding outlook remains valid.
- Outcome of the REGENXBIO arbitration and any resulting payment, license, royalty or infringement exposure.
- Progress, enrollment, safety and endpoint results for VIITAL and the ABO-102/ABO-101 trials, including the significance and durability of reported signals.
- Status of PPP loan forgiveness and any remaining repayment obligation.
- Subsequent financing, share issuance and dilution; year-end shares outstanding were 96.1 million, versus 98.8 million reported outstanding on March 19, 2021.
- Nasdaq board and audit committee compliance, and any impact of the disclosed governance deficiencies.